Search

Displaying results 6231 - 6240 of 10000 in total
  1. Drug

    Trolamine polypeptide oleate condensate

    go.drugbank.com/drugs/DB09373
    ApprovedVet approved

    Various ear diseases and infections are treated with eardrops containing triethanolamine polypeptide oleate-condensate, such as Cerumenex in the United States and Canada.

  2. Drug

    Nomegestrol acetate

    go.drugbank.com/drugs/DB13981
    Approved

    Nomegestrol acetate, also known as NOMAC, is a progestin used in oral contraceptives, menopausal hormone therapy, and for the treatment of gynecological disorders.

  3. Drug

    Trametes versicolor fruiting body

    go.drugbank.com/drugs/DB14287
    Investigational

    Trametes versicolor fruiting body is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  4. Drug

    Styphnolobium japonicum flower bud

    go.drugbank.com/drugs/DB14294
    Investigational

    Styphnolobium japonicum flower bud is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  5. Drug

    Chamaecyparis obtusa wood oil

    go.drugbank.com/drugs/DB14341
    Investigational

    Chamaecyparis obtusa wood oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  6. Drug

    Rosa centifolia flower oil

    go.drugbank.com/drugs/DB14363
    Investigational

    Rosa centifolia flower oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  7. Drug

    CG7870

    go.drugbank.com/drugs/DB04981
    Investigational

    CG7870 is an oncolytic virus therapy for prostate cancer.

  8. Drug

    Hesperetin

    go.drugbank.com/drugs/DB01094
    Investigational

    Hesperetin, in the form of its glycoside [hesperidin], is the predominant flavonoid in lemons and oranges.

  9. Drug

    AV-412

    go.drugbank.com/drugs/DB06021
    Investigational

  10. Drug

    MLN2222

    go.drugbank.com/drugs/DB06503
    Experimental

    MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.